In this issue:
Adverse events with JAK inhibitors and biologic DMARDs
Telitacicept for active systemic lupus erythematosus
Anterior uveitis in axial SpA treated with biologics or targeted synthetics
S100A4 monoclonal antibody for systemic sclerosis
Tocilizumab and abatacept spacing in RA in remission
Sex differences in effectiveness of first-line TNF inhibitors in PsA
Withdrawal of sarilumab for glucocorticoid-dependent sarcoidosis
Frailty and risk of serious infections in RA
Switch from upadacitinib to adalimumab in RA
Oral glucocorticoids in RA patients initiating TNF inhibitors, tocilizumab or abatacept
Please login below to download this issue (PDF)